Literature DB >> 10528184

Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus.

M A DeBenedette1, T Wen, M F Bachmann, P S Ohashi, B H Barber, K L Stocking, J J Peschon, T H Watts.   

Abstract

4-1BB ligand (4-1BBL) is a member of the TNF family expressed on activated APC. 4-1BBL binds to 4-1BB (CD137) on activated CD4 and CD8 T cells and in conjunction with strong signals through the TCR provides a CD28-independent costimulatory signal leading to high level IL-2 production by primary resting T cells. Here we report the immunological characterization of mice lacking 4-1BBL and of mice lacking both 4-1BBL and CD28. 4-1BBL-/- mice mount neutralizing IgM and IgG responses to vesicular stomatitis virus that are indistinguishable from those of wild-type mice. 4-1BBL-/- mice show unimpaired CTL responses to lymphocytic choriomeningitis virus (LCMV) and exhibit normal skin allograft rejection but have a weaker CTL response to influenza virus than wild-type mice. 4-1BBL-/-CD28-/- mice retain the CTL response to LCMV, respond poorly to influenza virus, and exhibit a delay in skin allograft rejection. In agreement with these in vivo results, allogeneic CTL responses of CD28-/- but not CD28+/+ T cells to 4-1BBL-expressing APC are substantially inhibited by soluble 4-1BB receptor as is the in vitro secondary response of CD28+ T cells to influenza virus peptides. TCR-transgenic CD28-/- LCMV glycoprotein-specific T cells are insensitive to the presence of 4-1BBL when a wild-type peptide is used, but the response to a weak agonist peptide is greatly augmented by the presence of 4-1BBL. These results further substantiate the idea that different immune responses vary in their dependence on costimulation and suggest a role for 4-1BBL in augmenting suboptimal CTL responses in vivo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10528184

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  54 in total

Review 1.  A novel helper role for CD4 T cells.

Authors:  J M den Haan; M J Bevan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

2.  Reverse signaling through the costimulatory ligand CD137L in epithelial cells is essential for natural killer cell-mediated acute tissue inflammation.

Authors:  Hye J Kim; Jong S Lee; Jung D Kim; Hee J Cha; Ahra Kim; Sun K Lee; Sang C Lee; Byoung S Kwon; Robert S Mittler; Hong R Cho; Byungsuk Kwon
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

3.  Analysis of costimulation by 4-1BBL, CD40L, and B7 in graft rejection by gene expression profiles.

Authors:  Rachel DeFina; Kenneth Christopher; Hongzhen He; Didier Mandelbrot; Yongping Gu; Patricia Finn; David L Perkins
Journal:  J Mol Med (Berl)       Date:  2003-08-22       Impact factor: 4.599

4.  Immune functions in mice lacking Clnk, an SLP-76-related adaptor expressed in a subset of immune cells.

Authors:  Oliver Utting; Bradley J Sedgmen; Tania H Watts; Xiaoshu Shi; Robert Rottapel; Angelo Iulianella; David Lohnes; André Veillette
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

Review 5.  The many sounds of T lymphocyte silence.

Authors:  Ignacio Melero; Ainhoa Arina; Lieping Chen
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 6.  Approaches to studying costimulation of human antiviral T cell responses: prospects for immunotherapeutic vaccines.

Authors:  Lena Serghides; Mariana Vidric; Tania H Watts
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

7.  4-1BB regulates NKG2D costimulation in human cord blood CD8+ T cells.

Authors:  Young-June Kim; Myung-Kwan Han; Hal E Broxmeyer
Journal:  Blood       Date:  2007-11-16       Impact factor: 22.113

8.  4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.

Authors:  Hua Zhang; Kristen M Snyder; Megan M Suhoski; Marcela V Maus; Veena Kapoor; Carl H June; Crystal L Mackall
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

9.  T cell costimulatory molecules in anti-viral immunity: Potential role in immunotherapeutic vaccines.

Authors:  Tania H Watts; Edward M Bertram; Jacob Bukczynski; Tao Wen
Journal:  Can J Infect Dis       Date:  2003-07

Review 10.  T-cell costimulatory blockade in organ transplantation.

Authors:  Jonathan S Maltzman; Laurence A Turka
Journal:  Cold Spring Harb Perspect Med       Date:  2013-12-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.